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Introduction {#s1}
============

Intra-aortic balloon pump (IABP) is the mechanical support device which is the one most frequently used in low cardiac output where the medical treatment is unsuccessful.^[@R1]^ By decreasing the afterload and increasing the pressure in roots of aorta, IABP leads the coronary arterial perfusion to increase. Hence, the myocardial oxygen requirement decreases. Since its use by Kantrowitz et al^[@R2]^ in 1968, IABP has been widely used in treatment of low cardiac output in many health care centers. The most frequent usage fields are unstable angina, complications developing secondary to ischemic cardiac disease, insufficient left ventricle function, and the low cardiac output syndrome developing during coronary heart surgery. Our aim in this study is to compare the complications in patients to whom the IABP with and without sheath has been implemented in our clinic.

Materials and Methods {#s2}
=====================

Between the years of 1985 and 2013, IABP has been implemented on a total of 3135 patients in our clinic. The study data has been obtained by retrospectively scanning the intensive care and operating theater records. The patients to whom the surgery has been implemented were grouped into 3 groups by IABP placement times as preoperative, intraoperative, and postoperative. The patients whom the balloon has been placed in intensive care unit before taking into operation were clustered in preoperative group, the ones whom the balloon has been placed during operation were clustered in intraoperative group, and the patients whom the balloon has been placed in intensive care unit follow-up after the operation were clustered in postoperative. The patients where the trans-femoral path has been used were clustered into 2 groups as use with and without sheath. These groups were compared in terms of developed complications. The patients where the IABP used with ECMO (extracorporeal membrane oxygenation) were excluded from the study.

Statistical methods {#s2-1}
-------------------

Statistical analyses were carried out by utilizing the SPSS (Statistical Package for the Social Sciences) version 15.0 software. The definitive analyses were provided by using frequency tables of categorical variables. While comparing the intergroup variables, the "Pearson chi-square test" was utilized. *P* \< 0.05 is accepted to be statistically significant.

Results {#s3}
=======

The mean age of the patients was 61.4 ± 13.2 years (16-82), and 2880 (92%) were males. Most of these patients had (70%) coronary artery disease (CAD). The demographical data of the patients are presented in [Table 1](#T1){ref-type="table"}. Cardiac surgery was applied to 2506 (80%) of the patients. Isolated CABG was implemented on 1842 (58.7%) patients. The CABGs performed off-pump were included in this group. IABP support was provided for 629 (20%) patients for medical treatment purpose. Among these patients, 235 (7.5%) patients were the ones with cardiomyopathy waiting for heart transplantation. The IABP usage indications are presented in [Table 2](#T2){ref-type="table"}. IABP has been implemented on 372 patients (11.8%) preoperatively, on 1246 (39.7%) patients postoperatively. The most frequent balloon implementation point was femoral artery with 3093 cases (98.7%). The balloon has been placed in percutaneous path in 2670 (85.2%) patients, and surgically in 423 (13.5%) patients. In percutaneous implementation, the balloon has been placed by sending to femoral artery through sheath until the year 2000. In this period, the balloon was implemented without sheath in patients having thin femoral artery. Since this date, the sheathless balloon placement method is adopted as routine. The diameter of the used balloon catheter was 8.5F or 9.0F. In 42 (1.3%) patients where it has not been placed in trans-femoral method, the alternative methods have been preferred. IABP implementation points are given in [Table 3](#T3){ref-type="table"}.

###### Demographic characteristics of patients

  --------------------------------------- -------- --------- -------
                                                   **No.**   **%**

  The mean age\                           Male     2880      92
  61.4 ± 13.2 (16-82)                                        

                                          Female   255       8

  Diabetes mellitus                       590      18.8      

  Hypertension                            602      19.2      

  Chronic obstructive pulmonary disease   258      8.2       

  Hyperlipidemia                          189      6         

  Smoking                                 1012     32.3      

  Peripheral artery disease               221      7         

  Coronary artery disease                 2204     70.3      

  Rheumatic valvular disease              438      14        

  Ischemic valve disease                  113      3.6       
  --------------------------------------- -------- --------- -------

###### Indications for use of IABP

  --------------------------------------- --------------------------------- --------- -------
                                                                            **No.**   **%**

  **Surgery group**                       2506                              80        

  I- Preoperative application (372)       CAD                               328       10.5

                                          Valve disease                     34        1.1

                                          Combinated                        10        0.3

  II- Intraoperative application (888)\   Isolated CABG                     831       26.5
  (end of pump )                                                                      

                                          Double procedures^a^              47        1.5

                                          Complex surgery^b^                10        0.3

  III- Postoperative Application (1246)   Isolated CABG                     1011      32.2

                                          Double procedures^a^              211       6.7

                                          Complex surgery^b^                24        0.8

  **Medical group**                       629                               20        

  Acute MI and complications, 304 (%)     1-Postinfarct VSD                 81        2.6

                                          2-Ischemic mitral insufficiency   52        1.6

                                          3- Left ventricular dysfunction   150       4.8

                                          4- Arrhythmia                     21        0.7

  Unstable angina pectoris                33                                1         

  LMCA                                    57                                1.8       

  Cardiomyopathy                          235                               7.5       
  --------------------------------------- --------------------------------- --------- -------

IABP: Inrtaaortic balloon pump, CAD: coronary artery disease, CABG: coronary artery bypass graft, MI: myocardial infarctus, VSD: ventricular septal defect, LMCA: left main coronary artery

^a^ The patients who applied 2 procedures with CABG either valvular or carotid surgery

^b^ The patients who applied 3 procedures as Bentall and CABG or CABG and double valve replacement.

###### IABP application areas

  ---------------------------- ---------------- ---------------- --------- -------
                                                                 **No.**   **%**

  Transfemoral, 3093 (98.7%)   Percutaneous\    With sheath      934       29.8
                               2670 (85.2%)                                

                                                Without sheath   1736      55.4

                               Surgical\        With sheath      160       5.1
                               423 (13.5%)                                 

                                                Without sheath   263       8.4

  Alternative routes\          Transthoracic\   Direct           10        0.3
  42 (1.3%)                    30 (0.1%)                                   

                                                Via graft        20        0.6

                               Transaxillary\   Direct           8         0.2
                               12 (0.4%)                                   

                                                Via graft        4         0.1
  ---------------------------- ---------------- ---------------- --------- -------

IABP: Intraaortic aort balloon pump.

^a^ The total number of patients used IABP between 1985 and 2013: 3135

The most frequently seen complication in patients whom the balloon has been placed was lower extremity ischemia (383, 12.2%). Surgical intervention was implemented on 204 (6.5%) patients. The embolectomy has been implemented mostly (153, 4.9%). In 4 patients with advanced ischemia, the amputation was implemented. In 4 of 42 patients whose IABPs were placed in alternative paths, the upper extremity ischemia developed. In 2 of them, the surgical intervention was required. Also in 44 (1.4%) patients, there was bleeding in balloon placement points. Even though hospital mortality was 814 (25.9%), only 5 of them occurred as a result of complications due to balloon ([Table 4](#T4){ref-type="table"}).

###### IABP complications

  --------------------------------------- -------------------------------- ------------ -------------------------------------- ----------- ---------
  **Complications**                                                                                                            ***No.***   ***%***

  **1-Extremity ischemia,** 387 (12.3%)   **Low extremity,** 379 (12%)     Medical                                             179         5.7

                                                                           Surgical\    Embolectomy                            153         4.9
                                                                           204 (6.5%)                                                      

                                                                                        Embolectomy + saphenous patch plasty   28          0.9

                                                                                        Embolectomy + graft interposition      8           0.2

                                                                                        Femoro-femoral bypass                  2           0.06

                                                                                        Fasciotomy                             5           0.1

                                                                                        Amputation                             4           0.1

                                          **Upper extremity,** 4 (0.12%)   Medical                                             2           0.06

                                                                           Surgical\    Embolectomy                            1           0.03
                                                                           2 (0.06%)                                                       

                                                                                        Embolectomy + graft interposition      1           0.03

  **2. Local bleeding**                   44                               1.4                                                             

  **3. Hemolysis**                        21                               0.7                                                             

  **4. Thrombocytopenia**                 16                               0.5                                                             

  **5. Infections**                       21                               0.7                                                             

  **6. Chronic serous discharge**         23                               0.7                                                             

  **7. Paraplegia**                       5                                0.1                                                             

  **8. Aortic complications,**\           **Dissection**                   \>3          \>0.1                                              
  7 (% 0.2)                                                                                                                                

                                          **Rupture**                      4            0.1                                                

  **9. Balloon Rupture**                  82                               2..6                                                            

  **10. Cerebral Embolism**               3                                0.1                                                             
  --------------------------------------- -------------------------------- ------------ -------------------------------------- ----------- ---------

IABP: Intraaortic aort balloon pump.

Paraplegia, which is a rare complication, developed in 5 patients. Thrombocytopenia developed in 16 patients, while hemolysis developed in 21 patients. In 7 patients, the aorta complication developed. Dissection occurred in 3 of these patients, and aorta rupture occurred in 4. And 4 of them were lost in early period. One of 3 patients where the cerebral emboli developed was lost in postoperative 35th day. The mortality due to balloon was found to be 0.16% with 5 patients ([Table 4](#T4){ref-type="table"}).

Discussion {#s4}
==========

The need for increased use of IABP during cardiac surgery in the recent years has been reported by many groups.^[@R3],[@R4]^ The first clinical application of IABP was in 1968 by Kantrowitz et al to support patients with cardiogenic shock due to myocardial infarction.^[@R2]^ The most frequently used one among the mechanical circulation support devices nowadays is the IABP. The most important reasons of that are its easy implementation, and its clear price advantage against other devices.^[@R5]^ IABP has two principal physiological effects; it improves coronary blood flow and myocardial oxygen supply by increasing diastolic perfusion pressure and reduces afterload by rapid balloon deflation in systole leading to reduced ventricular work and consequently decreased myocardial oxygen consumption.^[@R6]^ The real usage field of IABP, which is widely used in cardiology clinics and intensive care units, is the centers where the open cardiac surgery is applied. The aim of use in these centers can be divided into 3 as preventing the low cardiac output and severe myocardial ischemia in preoperative period, providing assistive support for patients who cannot leave the heart-lung device in intraoperative period, and preventing the low output in intensive care unit or medical-treatment-resistant arrhythmia in postoperative period.^[@R7]^ The most frequent balloon usage in patients whom we applied surgery in our clinic is in postoperative period with 1011 cases (32.2%).

Despite the positive hemodynamic effects of IABP, the complication rates related to IABPs are not low. In a study which reviewed the recent literature, the complication rates related to IABPs were reported to be between 32.6% and 50%.^[@R8]^ IABPs may lead to complications like thrombocytopenia, bleeding, injury to the aorta and iliac arteries, dissection, thromboembolism and leg ischemia. Thrombocytopenia and bleeding are the most commons complications.^[@R9]^ Additionally, complications related to malposition of the balloon catheter can be observed.^[@R10]^ Even though the incidence of arterial thrombosis and emboli development is decreased by implementing systemic heparinizing during IABP usage, the implementation's effect increasing the bleeding in postoperative period may lead to stop or delay the usage. Among these complications, the most frequently observed one was the upper extremity ischemia with 387 cases (12.3%) ([Table 4](#T4){ref-type="table"}). The extremity ischemia was observed in lower extremity where the balloon catheter was placed and in patients whom the device was implemented with sheath. Comparing with patients without sheath, the result was found to be statistically significant ([Table 5](#T5){ref-type="table"}). The longer the IABP support continues, the more the ischemia development rate in that extremity increases. The reason of that ischemia which the balloon causes is the damage on vessel wall during placing the balloon catheter, the prevention of blood circulation by catheter, and vasospasm occurring due to low cardiac output. Female gender, advanced age, diabetes, and atherosclerotic heart disease are the factors speeding this complication up, and the development of lower extremity ischemia in such patients was found to be more frequent. In patients where the balloon catheter cannot be placed via femoral artery, the transthoracic, axillary or subclavian artery path is an alternative.^[@R11]^ In our clinic implementation, we placed IABP to 42 patients where the trans-femoral path could not be used ([Table 2](#T2){ref-type="table"}). Among these patients, upper extremity ischemia developed in 4 patients, and surgical intervention was required in 2 of them. In order to minimize the vascular complications in IABP implementation, we generally prefer sheathless balloon catheter implementation. The advantage of this method is to decrease the mechanical obstruction. But there may be the bleeding as severe leakage in insertion point of balloon catheter ([Table 5](#T5){ref-type="table"}). Local bleeding was found to be more frequent in sheathless group (*P* = 0.03). This bleeding can be taken under control easily via purse sutures around the catheter. Bleeding occurred in 44 of our patients at balloon insertion point. In 21 patients, the infection developed in insertion point of balloon. 18 of these patients were the ones where the balloon was installed surgically because it could not be installed in percutaneous path. Thrombocytopenia developed in 16 patients. In these patients, the thrombocytopenia cleared up after heparin implementation was cut, and balloon was removed. Balloon rupture developed in 82 patients. The balloon rupture was found to be statistically significantly more frequent in sheathless group (*P* = 0.02). As a result of increased quality of used material and the technological developments, the balloon rupture is observed less frequently in recent years. The rapid flow of blood into the balloon catheter or inability of performing filling must make us think balloon rupture. In that case, the balloon must be removed immediately. Cerebral emboli developed in 3 patients. The reason of the emboli may be removal of atherosclerotic plaque from aortic or carotid tips of balloon catheter during installing the balloon. Or the air emboli due to balloon rupture may have led that. For this reason, the length must be measure on the patient before installing the balloon, and the location of the balloon must be checked through transesophageal echocardiography or teleradiograph after the balloon is installed. One of the patients where cerebral emboli developed due to balloon rupture died on postoperative 43th day due to low cardiac output. Aorta rupture developed in 4 patients. By taking 2 of these patients under surgery, the rupture in aorta was restored with graft. But other 2 patients died. Aorta dissection developed in 3 patients. Two of them died. And 1 of the patients was not intervened. In control tomography, it was seen that the rupture has limited. It is very hard to predict this catastrophic situation. In cases where it is hard to push the guide wire forward during the process, we recommend to assess the abdominal aorta pathologies through abdominal ultrasonography.

###### Hospital mortality

  --------------------------- ---------------------- --------- ------------ -------
                                                     **No.**   **Exitus**   **%**
  Surgical group                                     2506      709          28.3
                              Preoperative group     372       61           16.4
                              Intraoperative group   888       220          24.8
                              Postoperative group    1246      428          34.3
                              Transfemoral access    3093      801          25.9
                              Alternative access     42        13           30.1
  Medical group                                      629       105          16.7
  Balloon-related mortality                          3135      5            0.16
  Total hospital mortality                           3135      814          25.9
  --------------------------- ---------------------- --------- ------------ -------

Also the timing of IABP support is a controversial issue nowadays. The mortality is less than 20% in preoperative installation. But the mortalities in intraoperative and postoperative installations are almost 30% and 40%, respectively.^[@R12]^ Lavana et al evaluated the association between timing of IABP insertion and outcomes of the patients reporting mortality rates as 10% in preoperative group, 16% in the intraoperative group and 29% in the postoperative group. They concluded that preoperative IABP use was associated with reduction in hospital mortality.^[@R13]^ In study of Parissis et al, the preoperative mortality was found to be 18.2%, while the postoperative mortality was found to be 58.3%.^[@R14]^ Given results led to the suggestion of preoperative prophylactic IABP insertion in high risk patients before observing any hemodynamic compromise.^[@R15]^ In our study, the preoperative mortality was found to be 16.4%, while intraoperative mortality was found to be 24.8% and postoperative mortality was found to be 34.3%. Even though the total hospital mortality was 25.9%, the mortality due to balloon was found to be 0.16% ([Table 6](#T6){ref-type="table"}). The total hospital mortality in study carried out in our clinic at 1999 has been found to be 26.6%.^[@R16]^

###### Complication comparison in transfemoral IABP applications

  -------------------- -------------------------- ----------------------------- --------- ----- ------
                       **With sheath (n=1999)**   **Without sheath (n=1094)**   ***P***         
  **No.**              **%**                      **No.**                       **%**           
  Extremity ischemia   282                        14.1                          101       9.2   0\.
  Amputation           4                          0.2                           0         0     0.04
  Local bleeding       11                         0.5                           24        2.2   0.03
  Local infection      9                          0.4                           9         0.8   1
  Balloon rupture      26                         1.3                           42        3.8   0.02
  -------------------- -------------------------- ----------------------------- --------- ----- ------

IABP: Intraaortic aort balloon pump.

Conclusion {#s5}
==========

The IABP of nowadays is a mechanical support device which is still used safely and widely in treatment of low cardiac output developing after cardiac surgery. The easiness of implementation of this mechanical support is the main reason of that it is first preference in all kinds of intensive care units and open heart surgery. As a result of our IABP implementations in single center, we think that the preoperative and early-intraoperative balloon implementations are safer than intraoperative and postoperative implementations. Even though the complications due to balloon catheter decreased in recent years, they still occur. We recommend sheathless usage in order to prevent the extremity ischemia which is the most frequent complication developing due to IABP.

Limitations {#s6}
===========

This is a retrospective study, and not all the records of old patients could be reached. Since the medium- and long-term follow-ups of patients could not be reached, the long-term mortality rates could not be calculated.
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